ESR1 and breast carcinoma: Furthermore, a study on endocrine-resistant advanced breast cancers revealed that mutations in the mitogen-activated protein kinase (MAPK) pathway, transcriptional regulators of ER (MYC, CTCF, FOXA1, and TBX3), and ESR1 mutations were present in post-endocrine therapy tumors21.